About this compound
A co-lyophilized 1:1 blend of CJC-1295 (No DAC) and Ipamorelin, the two most frequently co-ordered sequences in the endocrine class.
Studied in
- Combined-protocol research
- GH/IGF-1 axis
- Receptor selectivity
Compound identity
| Compound | CJC-1295 + Ipamorelin |
|---|---|
| CAS number | 863288-34-0 / 170851-70-4 |
| Molecular formula | Co-lyophilized blend |
| Composition | Blend — component molecular weights: 3367.9 / 711.86 g/mol |
Specifications
- Purity method: HPLC
- Appearance: Lyophilized powder
- Solubility: Reconstitute per protocol; see Supplies for diluents.
- We don't publish a purity percentage here — that figure is only meaningful tied to the lot you actually receive, so it lives on the lot certificate.
Endocrine
CJC-1295 + Ipamorelin
Two growth-hormone peptides in one vial.
What the research targets
Studied together in combination protocols: CJC-1295 and ipamorelin, two routes to growth-hormone release.
Research use only
Supplied to qualified professionals and institutions for laboratory research. Not a drug, supplement or cosmetic, and not for human or veterinary use. We publish no dosing or administration guidance of any kind.
Supply formats
Buy one, or a case of ten.
Single unit
One unit.
10 mg totalVial
PS-9043831-10-MG-TOTAL
On verified account
Case — 10-pack
10 of the same size, at the 10-pack price.
Case · 10 × 10 mg total
10-pack price — 10 × one unit, per vial.
PS-9043831-C10-10-MG-TOTAL
On verified account
One-time verification of professional or institutional affiliation. No payment is taken on this site.
From the research library
All articlesCited summaries of the published work behind CJC-1295 + Ipamorelin — what was studied, in which model, and what was measured.
Endocrine
Hexarelin, and the receptor nobody was looking for
Growth-hormone-releasing peptides were built for one receptor. A Montreal group found hexarelin bound to a second one, in the heart, and the two literatures have run side by side since.
Endocrine
The growth-hormone axis, and four ways to poke it
GHRH analogues and ghrelin-receptor peptides push growth hormone in different ways. That difference is the whole story.